Snorx, Inc. Taps Medical Technology Industry Veteran Alexander K. Arrow, MD as Chief Executive Officer
LAKE FOREST, CA (January 7, 2015) – Snorx, Inc., the developer of an innovative minimally invasive surgical interventional anti-snoring device, today reported that Alexander K. Arrow, M.D. has been appointed Chief Executive Officer and will be leading the company as it enters its regulatory submission phase and prepares to manufacture its first product.
Dr. Arrow comes to Snorx, Inc. from Biolase, Inc. (NASDAQ: BIOL), the world’s lead manufacturer and seller of dental lasers, where he served as a President and Chief Operating Officer, a Director, and Chair of the Audit and Compensation committees of the Board of Directors among other roles. Prior to Biolase, Dr. Arrow was the Chief Medical Officer of Stanford-affiliated neuroscience company Circuit Therapeutics, Inc., and prior to that he spent five years as the Chief Financial Officer of cardiovascular device manufacturer Arstasis, Inc.
Before entering operating roles, Dr. Arrow spent nine years running medical technology equity research at three Wall Street firms, the last five years at Lazard. He also served as the Chief Financial Officer of the Patent & License Exchange, Inc. He has an MD from Harvard Medical School and began his surgical residency at the UCLA Medical Center before leaving to go into business.
“We are delighted to have someone of Alex’s caliber as CEO of Snorx,” said Dr. Yosef Krespi, MD, FACS, the Director of the Center for Sleep Disorders, NYHNI, as well as Professor of Clinical Otolaryngology at Columbia University, and one of the co-founders of Snorx, Inc. “We were looking for someone with the right mix of management experience, start-up growth experience, and surgical background. In Alex, we found all three.”
About Zelegent, Inc.
Zelegent, Inc. (formerly Snorx, Inc.), is a medical technology company that is developing, and plans to manufacture and market, innovative tools for physicians who treat sleep disorders. Zelegent was co-founded by two of the world’s leading authorities on sleep disorders, Dr. Yosef P. Krespi who heads the New York Head and Neck Institute Sleep Disorder Center, and Dr. David O. Volpi, founder of the eOs Sleep Network (formerly the Manhattan Sleep Center). The company’s mission is to develop and commercialize a novel minimally-invasive surgical tool to be used by sleep specialist otolaryngologists to treat snoring by shortening, suspending, and stiffening the patient’s soft palate, the source of most snoring. The Zelegent tool is an investigational device only and is not for sale in the United States.
Comments are closed